Compare Dollar General Corp. (DG) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Zoetis Inc — how do they compare? Dollar General Corp. trades at $124.93 (market cap $27.42B), while Zoetis Inc trades at $74.62 (market cap $30.20B). The key difference: Dollar General Corp. and Zoetis Inc are close in size by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Zoetis Inc for 70 Days on average.
| DG | ZTS | |
|---|---|---|
Market Cap | $27.42B | $30.20B |
Volume | 2,291,517 | 6,175,327 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $147.53 |
52-Week Low | $95.94 | $69.09 |
Typical Hold Time | 59 Days | 70 Days |
Enterprise Value | $41.60B | $37.76B |
Dividend Yield | 1.9% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $122.16, down 0.89% on the day, with a neutral technical signal. The stock shows strong fundamentals with a P/E of 16.14 and P/S of 0.63, indicating potential undervaluation. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $2.48 surpassing the $2.01 expectation. Positive news includes tariff refunds boosting margins and expansion of same-day delivery via Instacart, supporting growth initiatives.
The outlook is cautiously optimistic, with a consensus price target of $137.27 offering ~12% upside. Key opportunities include margin improvement from operational initiatives, while risks involve competitive pressures and potential consumer spending softness. Analyst sentiment is predominantly buy-rated (55.77%), though recent insider selling and mixed technical indicators warrant monitoring.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed earnings performance, having beaten estimates in Q2 2026 but missing in Q1. Despite recent headwinds in U.S. companion animal sales, the company maintains strong profitability with 71.67% gross margins and 27.69% net income margins. Analyst consensus remains positive with a $87.33 price target, though technical indicators suggest near-term pressure with support at $70-$71.
Zoetis presents a compelling value opportunity with attractive valuation multiples (P/E 11.92, EV/EBITDA 9.4) and robust fundamentals, though near-term risks include competitive pressures in pet medications and weakening U.S. veterinary clinic traffic. The company's international and livestock segments show resilience, supporting long-term growth potential despite current market skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
